Literature DB >> 8318069

Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas?

P Wolf1, E Rieger, H Kerl.   

Abstract

BACKGROUND: Topical photodynamic therapy with endogenous porphyrins consists of irradiation of a tumor with visible light after the application of exogenous 5-aminolevulinic acid.
OBJECTIVE: To assess the effectiveness of this modality, patients with precancerous conditions and various skin cancers were treated.
METHODS: Thirteen patients with 70 skin lesions were enrolled. Standard treatment involved the topical application of 20% 5-aminolevulinic acid in an oil-in-water emulsion. The emulsion was applied under an occlusive dressing for 4 to 8 hours before exposure to photoactivating light.
RESULTS: We observed a complete response after a single treatment for all 9 solar keratoses, 5 of 6 early invasive squamous cell carcinomas, and 36 of 37 superficial basal cell carcinomas. Only 1 of 10 nodulo-ulcerative basal cell carcinomas completely resolved. Eight cutaneous metastases of malignant melanoma were therapeutic failures.
CONCLUSION: Topical photodynamic therapy with endogenous porphyrins is effective for superficial epithelial skin tumors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318069     DOI: 10.1016/0190-9622(93)70002-b

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  26 in total

1.  Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells.

Authors:  R Bachor; E Reich; A Rück; R Hautmann
Journal:  Urol Res       Date:  1996

2. 

Authors:  C S Betz; A Leunig
Journal:  HNO       Date:  2004-02       Impact factor: 1.284

Review 3.  Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives.

Authors:  F S De Rosa; M V Bentley
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

Review 4.  Photodynamic therapy of cancer: an update.

Authors:  Patrizia Agostinis; Kristian Berg; Keith A Cengel; Thomas H Foster; Albert W Girotti; Sandra O Gollnick; Stephen M Hahn; Michael R Hamblin; Asta Juzeniene; David Kessel; Mladen Korbelik; Johan Moan; Pawel Mroz; Dominika Nowis; Jacques Piette; Brian C Wilson; Jakub Golab
Journal:  CA Cancer J Clin       Date:  2011-05-26       Impact factor: 508.702

5.  Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism.

Authors:  C Fritsch; B Verwohlt; K Bolsen; T Ruzicka; G Goerz
Journal:  Arch Dermatol Res       Date:  1996-08       Impact factor: 3.017

6.  Nanoscale Metal-Organic Layer Isolates Phthalocyanines for Efficient Mitochondria-Targeted Photodynamic Therapy.

Authors:  Geoffrey T Nash; Taokun Luo; Guangxu Lan; Kaiyuan Ni; Michael Kaufmann; Wenbin Lin
Journal:  J Am Chem Soc       Date:  2021-02-02       Impact factor: 15.419

Review 7.  Photodynamic therapy in the treatment of cancer: current state of the art.

Authors:  R A Hsi; D I Rosenthal; E Glatstein
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 8.  [Therapy of cutaneous metastases of malignant melanoma].

Authors:  P Rehberger; S Eppinger; A Stein; J Schmitt
Journal:  Hautarzt       Date:  2006-12       Impact factor: 0.751

9.  Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin.

Authors:  Elaine G Rodrigues; Andrey Ss Dobroff; Clarissa F Cavarsan; Thaysa Paschoalin; Leonardo Nimrichter; Renato A Mortara; Edson Lucas Santos; Marcos A Fázio; Antonio Miranda; Sirlei Daffre; Luiz R Travassos
Journal:  Neoplasia       Date:  2008-01       Impact factor: 5.715

10.  Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment.

Authors:  A Martin; W D Tope; J M Grevelink; J C Starr; J L Fewkes; T J Flotte; T F Deutsch; R R Anderson
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.